Amgen Inc Stock Plunges 10.1%, GuruFocus Estimates Overvaluation

Amgen Inc (AMGN) shares saw a significant decline of 10.1% to $393.17 on September 8, 2026, marking a notable drop amid its 52-week trading range of $269.77 to $447.03.

This setback comes after the stock's impressive year-long performance, with a gain of 44.2% over the past 12 months.

According to GuruFocus' proprietary estimate, GF Value, Amgen is currently overvalued by approximately 7.5%, with its current price exceeding its estimated intrinsic value of $365.80.

The company's strong fundamentals are reflected in its GF Score of 85/100, which highlights solid profitability and growth prospects, but also reveals concerns regarding financial strength and insider selling activity.